{
    "nctId": "NCT05896865",
    "briefTitle": "Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer",
    "officialTitle": "Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer: Non-randomized Phase II, Prospective Single Arm Study Clinical Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Stage III",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "5-year disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female with age 19 or older\n* Metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy\n* Underwent neoadjuvant chemotherapy\n* Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy\n* Eastern Cooperative Oncology Group performance status 0-2\n* Informed consent\n\nExclusion Criteria:\n\n* Previous history of radiation therapy to the chest\n* Distant metastasis",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}